NEUROENDOCRINE TUMORS

This study is testing how well an oral medication called surufatinib works for people with advanced neuroendocrine tumors in real-world medical settings. About 350 patients will take the medication daily and be monitored for tumor response, side effects, and quality of life. The …

This early-phase study is testing a new type of cell therapy for people with advanced solid tumors, including melanoma, that have spread and are not responding to standard treatments. Doctors take a patient's own immune cells, modify them in a lab to better recognize and attack c…

This study is testing a more flexible way to give the cancer drug cabozantinib to people with advanced kidney cancer or neuroendocrine tumors. The goal is to see if adjusting the dose up or down based on how patients feel can help them stay on treatment longer with fewer severe s…

This study is testing whether giving two more cycles of Lutathera treatment helps people whose intestinal neuroendocrine tumors have started growing again after previous Lutathera therapy. Researchers will compare giving the extra treatment against simply monitoring the cancer wi…

This study is testing a new radioactive drug called Terbium-161 DOTATATE for people with advanced neuroendocrine tumors that have spread and have stopped responding to the current standard radiation therapy. The goal is to see if this new drug is safe and can better control the c…

This study aims to see if a new targeted radiation treatment (177Lu-edotreotide) works better than the standard pill (everolimus) for people with advanced neuroendocrine tumors in the lungs or thymus gland. It will involve about 120 adults whose tumors have grown despite prior tr…

This is the first study in people to test a new oral medication called CID-078 for advanced solid tumors. The main goals are to find a safe dose and see how well the body handles the drug. The study will enroll adults with cancers like triple-negative breast cancer, small cell lu…

This study is testing whether customizing radiation therapy for each patient works better than the standard one-size-fits-all approach for advanced neuroendocrine tumors. Researchers will compare how long the cancer stays under control, side effects, and quality of life between t…

This study is testing a new personalized cell therapy called CHM-2101 for people with advanced stomach, colon, or neuroendocrine cancers that have come back or stopped responding to standard treatments. Doctors will collect a patient's own immune cells, modify them in a lab to be…

This early-stage clinical trial is testing a new drug called CRN09682 for people with advanced neuroendocrine tumors and other solid tumors that have a specific marker (SST2). The main goals are to find a safe and tolerable dose and to see if the drug shows early signs of helping…

This study is observing how well the cancer drug cabozantinib works and how safe it is for adults with advanced neuroendocrine tumors (NETs) who have already tried at least one other treatment. It will follow about 150 patients in Germany and Austria who are already receiving thi…

This study is testing an experimental radioactive drug called Lu-177-DOTATATE for adults with rare adrenal or nerve-related tumors that cannot be removed by surgery. The main goals are to see if the treatment is safe and if it can help patients live longer without their cancer ge…

This early-stage study is testing a new drug called Sapu003 in people with advanced cancers that have spread or cannot be removed by surgery. The main goal is to find the safest and most effective dose, and to see how the body processes the drug. The study includes 27 adults with…

This early-stage study is testing a new approach for patients with advanced neuroendocrine tumors that have spread. The goal is to see if taking a pill (ASTX727) for five days can 'switch on' a specific target on the cancer cells, making a follow-up radioactive therapy (Lutathera…

This study aims to see if a special type of PET scan (using Detectnet) can help doctors plan Lutathera radiation therapy more safely for people with neuroendocrine tumors. Researchers want to use the scan to better predict how much radiation reaches tumors versus healthy organs, …

This study is testing whether combining two treatments—oral chemotherapy (CapTem) and a targeted radiation procedure (Y90 radioembolization)—is safe and can better control the growth of advanced neuroendocrine tumors in the liver. It is for patients whose cancer has spread to the…

This early-stage trial is testing a new cancer drug called NN3201 for the first time in people. The study aims to find a safe dose and see how well the drug works against several advanced solid tumors that have a specific protein called c-Kit. Researchers will enroll 67 adults wi…

This is the first-ever study in people for a new drug called ADCT-701, designed for adults with rare and hard-to-treat cancers like neuroendocrine tumors and malignant peripheral nerve sheath tumors. The main goal is to find the safest and most effective dose by giving the drug t…

This study is testing whether a combination of two existing cancer drugs, lenvatinib and pembrolizumab, can help control a rare and aggressive type of neuroendocrine tumor. It will enroll 29 adults with a specific, fast-growing tumor type that has spread or cannot be removed by s…

This study is testing whether combining two drugs, Lutathera and Olaparib, can shrink rare neuroendocrine tumors in the digestive system or pancreas that cannot be removed by surgery. About 56 adults will receive Lutathera through an IV every 8 weeks and take Olaparib pills twice…

This early-stage trial is testing a new combination treatment for patients with advanced neuroendocrine tumors that have progressed after standard therapy. Researchers are combining an experimental virus designed to attack cancer cells (SVV-001) with two established immunotherapy…

This is the first study in people to test a new drug called BL-M14D1 for advanced cancers that have spread or cannot be removed by surgery. The main goal is to find a safe dose and see how the body processes the drug in about 22 adults with certain cancers, including small cell l…

This study is testing a personalized cell therapy for people with metastatic cancer that has not responded to standard treatments. Doctors take a patient's own white blood cells, genetically modify them in a lab to better recognize and attack their specific cancer, and then infus…

This study is testing if follow-up care for certain rare cancers can be done just as well remotely by a nurse over the phone, compared to traditional in-person visits with a doctor at the hospital. It aims to see if patients stick to their recommended check-up schedule better wit…

This study is testing whether a new radioactive drug called RYZ101 works better than standard treatments for advanced neuroendocrine tumors of the gut and pancreas. It's for people whose tumors have grown despite previous radiation therapy. The trial will measure how long the dru…

This early-stage study is testing a new imaging tracer to see if it can help doctors better tell the difference between cancer and normal tissue on a PET/CT scan. Researchers will give the tracer to 24 adults with specific cancers, including brain, breast, and rectal tumors, to s…

This study is testing a new blood marker called hPG80 to see if it can help find neuroendocrine tumors earlier in people with a rare inherited condition called MEN1. Currently, people with MEN1 need frequent, stressful scans and tests to check for these tumors. The goal is to see…

This study is testing an improved version of a special PET scan called 18F-DOPA. The goal is to see if using a newer scanner and a common medication (furosemide) can make the images clearer, especially in the lower abdomen. This could help doctors better detect and plan treatment…

This study is testing a new imaging agent called 89Zr-TLX250 to see if it can help doctors better detect and locate three specific types of cancer using a PET-CT scan. The trial will involve 60 adults with liver cancer, bile duct cancer, or certain neuroendocrine tumors. The main…

This study is testing if guarana, a plant-based supplement, can help reduce severe fatigue in people with certain cancers. It will enroll 86 adults with neuroendocrine tumors or gynecologic cancers who report significant fatigue. Participants will take guarana or a placebo for se…

This study aims to better understand how patients with advanced neuroendocrine tumors (NETs) respond to a treatment called Peptide Receptor Radionuclide Therapy (PRRT). Researchers will collect detailed information from about 50 patients receiving this standard treatment to learn…

This study aims to understand how pancreatic tumors develop in people with von Hippel-Lindau (VHL) disease, a rare genetic condition. Researchers will follow 740 participants aged 12 and older over many years, using regular scans and tests to track tumor growth. The study will te…

This study is testing a new artificial intelligence (AI) tool designed to help match people with advanced cancer to suitable clinical trials. It will enroll up to 50,000 patients to see if using this AI system makes it easier for patients to find and join trials. The researchers …

This study is creating a database of health information and blood samples from cancer patients receiving targeted radiation therapy. Researchers will collect data from 350 adults with thyroid, prostate, or neuroendocrine cancers to better understand how these treatments work and …

This study is building a large, long-term database of health information and biological samples from people with cancer, people at risk for cancer, and healthy volunteers. The goal is to collect this data to help researchers better understand what causes cancer and how to prevent…

This study aims to understand why some patients with neuroendocrine tumors respond better to treatments than others. Researchers will analyze medical records from 450 patients who received standard treatments to identify factors that influence how long treatments keep the cancer …

This study aims to learn more about rare neuroendocrine cancers by observing people who have them over their lifetime. Researchers will collect blood, saliva, and tumor samples from up to 300 participants to understand how these cancers progress and what treatments work best. The…